LICENSE AGREEMENTLicense Agreement • May 19th, 2014 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (this “Agreement”) dated as of December 12, 2013 (the “Effective Date”), is entered into between Cabaret Biotech Ltd. (“Cabaret”), a company incorporated in Israel with an address at 14 Marva St., Rehovot 7630950, Israel, Dr. Zelig Eshhar (“Dr. Eshhar”), an individual, and KITE PHARMA, INC. (“Kite”), a Delaware corporation, with an address at 10924 Le Conte Avenue, Los Angeles, California 90024, USA.
THE NATIONAL INSTITUTES OF HEALTH PATENT LICENSE AGREEMENT — EXCLUSIVE/CO- EXCLUSIVE COVER PAGEPatent License Agreement • May 19th, 2014 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options). The Parties to this Agreement are:
PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCHCooperative Research and Development Agreement • May 19th, 2014 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
SERVICES AGREEMENTServices Agreement • May 19th, 2014 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • New York
THIS SERVICES AGREEMENT (“Agreement”) is entered into effective as of June 1, 2009 (the “Effective Date”), by and between KITE PHARMA, INC., a Delaware corporation (“KITE”) having a place of business at 689 5th Avenue, l2th Floor, New York, NY 10022 and TWO RIVER CONSULTING, LLC, a Delaware limited liability corporation (“CONSULTANT”), having a business address at 689 Fifth Avenue, 12th Floor, New York, NY 10022.
KITE PHARMA, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • May 19th, 2014 • Kite Pharma, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amended and Restated Investors’ Rights Agreement (this “Agreement”) is made as of this 25th day of April, 2014, by and among KITE PHARMA, INC., a Delaware corporation (the “Company”), the KEY MANAGEMENT STOCKHOLDERS (as defined herein), the SERIES A INVESTORS (as defined herein) and the BRIDGE INVESTORS (as defined herein).
